Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Strategic behaviour

Strong strategising depends on your colleagues’ behaviour

- PMLiVE

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.

Avalere Health

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

- PMLiVE

AbbVie’s Rinvoq approved by MHRA for Crohn’s disease

Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms

A bundle of nerves

Medical experts have determined that we need to screen everyone for anxiety − and I mean everyone

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

- PMLiVE

Kite and Arcellx close multiple myeloma collaboration agreement

This haematological malignancy is the third most common  in Europe and the US and is incurable for most patients

- PMLiVE

Patient Recruitment: Think Global, Act Local

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust...

- PMLiVE

The challenges of identifying rare diseases

With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

- PMLiVE

Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis

Spesolimab prevented flares in adolescents and adult GPP patients for up to 48 weeks

- PMLiVE

Microfoundations matter

If you want to change in 2023, sweat the small stuff

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links